High-dose therapy with autologous transplantation for Hodgkin's disease: The Bologna experience

Pier Luigi Zinzani, Monica Tani, Annalisa Gabriele, Filippo Gherlinzoni, Antonio De Vivo, Paolo Ricci, Giuseppe Bandini, Roberto Massimo Lemoli, Maria Rosa Motta, Simonetta Rizzi, Valeria Giudice, Maurizio Zompatori, Vittorio Stefoni, Lapo Alinari, Gerardo Musuraca, Simona Bassi, Roberto Conte, Stefano Pileri, Sante Tura, Michele Baccarani

Research output: Contribution to journalArticle

Abstract

Background and Objectives. In this work we examine the characteristics and outcome of patients with Hodgkin's disease (HD) treated with high-dose therapy (HDT) and autologous transplantation at our Institute between 1982 to 2000. Design and Methods. A retrospective analysis was performed examining patients' characteristics, prior chemotherapy regimens, pre-transplant disease status, HDT regimen, source of stem cells, time for hematopoietic recovery, complications of transplantation, response rates, overall survival (OS) and relapse-free survival (RFS). Results. Ninety-seven patients with HD were treated and had estimated 10-year OS and RFS rates of 32% and 60%, respectively. Disease status (sensitive vs. refractory) before HDT was the most powerful predictive parameter for OS and RFS in both univariate and multivariate analyses. The rate of transplant-related mortality in the whole cohort was only 1% whereas the rate of second malignancies was 3%. Interpretation and Conclusions. Our results confirm that HDT with autologous transplantation is associated with a durable RFS in a remarkable proportion of HD patients and that the procedure has a very low global early and late toxicity.

Original languageEnglish
Pages (from-to)522-528
Number of pages7
JournalHaematologica
Volume88
Issue number5
Publication statusPublished - May 1 2003

Keywords

  • ABMT
  • Chemotherapy
  • Hodgkin's disease
  • Relapse-free survival

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'High-dose therapy with autologous transplantation for Hodgkin's disease: The Bologna experience'. Together they form a unique fingerprint.

  • Cite this

    Zinzani, P. L., Tani, M., Gabriele, A., Gherlinzoni, F., De Vivo, A., Ricci, P., Bandini, G., Lemoli, R. M., Motta, M. R., Rizzi, S., Giudice, V., Zompatori, M., Stefoni, V., Alinari, L., Musuraca, G., Bassi, S., Conte, R., Pileri, S., Tura, S., & Baccarani, M. (2003). High-dose therapy with autologous transplantation for Hodgkin's disease: The Bologna experience. Haematologica, 88(5), 522-528.